Twist Bioscience 10-Qquarter ended 2025-06-30

Executive Summary

Twist Bioscience’s fiscal Q3 ended 6/30/2025 delivered 18% Y/Y revenue growth and a 10.1 percentage-point gross-margin expansion, showing that higher NGS and synthetic-gene volumes plus manufacturing efficiencies are improving the core business model. However, the $20.4M quarterly profit was created by a $48.8M gain on the Atlas data-storage divestiture; core operations still produced a $30.1M loss, with SG&A absorbing more than gross profit. The divestiture concentrates resources on synthetic DNA/RNA, NGS tools and biopharma discovery while preserving speculative Atlas upside, but it also replaces direct operating exposure with an illiquid, valuation-sensitive investment. Investors should view improving margins and lower cash burn as evidence of progress, while requiring continued operating leverage to validate a path to recurring profitability without further dilution or monetization of future economics.

Key Financial Highlights

• Revenue mix: NGS tools $55.3M, +27% Y/Y and 57% of Q3 revenue; synthetic genes $27.7M, +11%; DNA libraries $2.1M, -47%. Healthcare contributed $56.4M, or 58%, while APAC declined 9%, exposing concentration in NGS, healthcare and Western markets.
• YTD economics: Revenue $277.6M, +21.6%; gross profit $140.2M at a 50.5% margin vs 41.7%; operating loss $(106.3)M; the margin trajectory is improving faster than revenue, but has not yet overcome the expense base.
• Operating expenses: Q3 R&D fell 20% to $18.0M, partly from transferring data-storage employees, while SG&A rose 12% to $63.4M and exceeded gross profit. This makes SG&A control the principal remaining operating-leverage test.
• Stock-based compensation: $16.1M in Q3 and $48.4M YTD, ≈17% of YTD revenue; 60.2M shares were outstanding vs 58.9M at FY2024-end, with $117.8M of unrecognized standard and performance-RSU expense creating continuing dilution and cost pressure.
• Liquidity and cash flow: Cash and short-term investments were $250.8M; YTD operating cash use improved to $(35.8)M from $(48.8)M, while capex was $15.6M. Including the $54.3M Atlas investment, cash, investments and securities totaled $305.1M, but Atlas is not equivalent to operating liquidity.
• Financing obligations: TWST received $15.0M from XOMA in exchange for half of specified future milestone and royalty receipts, recorded as a debt-like liability; operating lease liabilities were $78.2M, with $122.8M of undiscounted payments through 2044.

Business Developments

TWST sold its DNA digital data-storage business to Atlas Data Storage on 5/2/2025, allowing management to redirect people and capital toward synthetic DNA/RNA, NGS products, antibody libraries, proteins and biopharma collaborations. Consideration included $2.5M cash, a note valued at $1.7M and 73.0M Atlas preferred shares valued at $53.9M, plus up to $75.0M of milestones and future royalties.

Management retains significant influence through one of seven Atlas board seats but does not consolidate Atlas. The transaction removes direct responsibility for funding data storage while preserving upside; conversely, TWST’s maximum Atlas-related loss exposure was $57.4M, and realization depends on Atlas’s execution, preferred liquidation structure and access to liquidity.

Core commercial indicators strengthened: quarterly purchasing customers rose to ≈2,484 from 2,300, while genes shipped increased 12% to ≈237,000. Management attributes margin expansion to greater volume, process improvements, manufacturing savings and lower depreciation after prior impairments, making utilization of the Wilsonville facility a key mechanism for further operating leverage.

Risk Assessment

• Recurring-profitability risk: Q3 operating loss was $(30.1)M despite a 53.4% gross margin; the reported profit depended on a one-time $48.8M disposal gain.
• Expense and dilution risk: SG&A of $63.4M exceeded quarterly gross profit, while $48.4M of YTD stock compensation and expanded equity-plan capacity could limit per-share benefits from growth.
• Atlas valuation and concentration risk: Maximum exposure was $57.4M in illiquid securities, notes and receivables whose value depends on private-company assumptions, liquidation preferences and Atlas’s commercial success.
• Liquidity and capital-allocation risk: Liquid cash and short-term investments declined to $250.8M from $276.4M at FY2024-end; continuing operating losses, $10.3M of capex commitments and facility investment could require additional financing.
• Commercial concentration risk: NGS supplied 57% of Q3 revenue and healthcare 58%; weakness in either could materially slow growth, while DNA libraries fell 47% and APAC revenue declined 9%.
• Future-revenue financing risk: XOMA received rights to 50% of specified future milestones and royalties, improving current liquidity at the cost of surrendering potential future economics under a Level 3-estimated liability.
• Litigation risk: Securities and derivative actions concerning DNA-product and accounting disclosures remain unresolved; no potential loss can yet be estimated.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: the company's 10-Ks on SEC.

Strategic Outlook and Investor Actionables

TWST is becoming a more focused, higher-margin life-sciences platform, with NGS growth and manufacturing efficiency supporting the clearest route to breakeven. The near-term thesis requires gross-profit expansion to outpace SG&A and cash consumption; Atlas-related gains, milestones or valuation changes should be separated from recurring performance.

• Operating leverage: Monitor gross margin, SG&A and operating loss; sustained margin above 50% combined with declining SG&A as a percentage of revenue would confirm progress toward recurring profitability.
• Growth quality: Monitor NGS and synthetic-gene growth alongside purchasing customers and shipment volumes; broader product and geographic growth would reduce current concentration.
• Cash and dilution: Monitor operating cash burn, liquid resources, stock compensation and share count; lower burn without additional future-revenue sales or material issuance would strengthen the per-share thesis.